AR106037A1 - Moduladores de la proteína core de la hepatitis b - Google Patents
Moduladores de la proteína core de la hepatitis bInfo
- Publication number
- AR106037A1 AR106037A1 ARP160102816A ARP160102816A AR106037A1 AR 106037 A1 AR106037 A1 AR 106037A1 AR P160102816 A ARP160102816 A AR P160102816A AR P160102816 A ARP160102816 A AR P160102816A AR 106037 A1 AR106037 A1 AR 106037A1
- Authority
- AR
- Argentina
- Prior art keywords
- 6alkyl
- optionally substituted
- group
- hydroxyl
- halogen
- Prior art date
Links
- 101710132601 Capsid protein Proteins 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical class 0.000 abstract 8
- 125000001424 substituent group Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- -1 proprenyl Chemical group 0.000 abstract 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000012637 allosteric effector Substances 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D281/16—[b, f]-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D267/20—[b, f]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proveen, en parte, compuestos que tienen propiedades efectoras alostéricas contra la Cp del virus de la Hepatitis B. También se proveen métodos de tratamiento de infecciones virales, tal como la hepatitis B, que comprenden administrar a un paciente que lo necesita uno de los compuestos divulgados. Reivindicación 1: Un compuesto caracterizado porque está representado mediante la fórmula (1) donde Y se selecciona del grupo que consiste en S(O)ʸ, C=O, C(R¹¹)₂, NRY y O donde y es 0, 1, ó 2; R¹¹ es H o C₁₋₆alquilo, RY se selecciona del grupo que consiste en H, metilo, etilo, propilo, proprenilo, fenilo y bencilo, donde RY, cuando no es H, puede estar opcionalmente sustituido con hidroxilo; RZ se selecciona del grupo que consiste en H, metilo, etilo, propilo, fenilo y bencilo; Rᵐ y Rᵐ se seleccionan en forma independiente entre sí del grupo que consiste en H y C₁₋₆alquilo (opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados cada uno de forma independiente entre halógeno e hidroxilo); L es una unión o C₁₋₂alquileno (opcionalmente sustituido con halógeno o C₁₋₂alquilo); A es un anillo monocíclico heterocíclico de 5 - 7 miembros o monocíclico heteroarilo de 5 - 6 miembros opcionalmente sustituido con uno o dos sustituyentes seleccionados del grupo que consiste en halógeno, hidroxilo, ciano, C₁₋₆alquilo, C₂₋₆alquenilo, C₂₋₆alquinilo, C₁₋₆alcoxi, y NRR; B se selecciona del grupo que consiste en fenilo (opcionalmente sustituido con uno, dos o tres sustituyentes representados mediante R³³), heteroarilo monocíclico de 5 - 6 miembros (opcionalmente sustituido con uno, dos o tres sustituyentes representados mediante R³³), y heteroarilo bicíclico de 9 - 10 miembros (opcionalmente sustituido con uno, dos o tres sustituyentes representados mediante R³³); R se selecciona, en forma independiente en cada caso, entre H, metilo, etilo, y propilo; R se selecciona, en forma independiente en cada caso, entre H, metilo, etilo, propilo (opcionalmente sustituido con hidroxilo), butilo (opcionalmente sustituido con hidroxilo), -C(O)-metilo y-C(O)-etilo, o R y R tomados junto con el nitrógeno al cual están unidos pueden formar un heterociclo de 4 - 7 miembros opcionalmente sustituido con uno, dos o más sustituyentes seleccionados del grupo que consiste en halógeno, hidroxilo, NH₂, -C(O)-O-C₁₋₃alquilo, -C(O)-C₁₋₃alquilo, carboxi, oxo, y C₁₋₃alquilo; cada una de las porciones R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, y R¹⁰ se selecciona en forma independiente en cada caso entre el grupo que consiste en hidrógeno, C₁₋₆alquilo, C₂₋₆alquinilo, C₂₋₆alquenilo, halógeno, hidroxilo, nitro, ciano, y NRR; R³³ se selecciona en forma independiente en cada caso entre el grupo que consiste en H, halógeno, hidroxilo, nitro, ciano, C₁₋₆alquilo, -C(O)-O-C₁₋₆alquilo, -C(O)-NRR, -C(=NH)-NRR, C₂₋₆alquenilo, C₂₋₆alquinilo, C₁₋₆alcoxi, carboxi, -CHO, NRR, -C(O)-C₁₋₆alquilo, -C(O)-C₁₋₆alcoxi, C₃₋₆cicloalquilo, -S(O)ʷ-C₁₋₆alquilo (donde w es 0, 1 ó 2), -S(O)ʷ-NRR (donde w es 0, 1 ó 2), y NR-S(O)ʷ-C₁₋₆ alquilo (donde w es 0, 1 ó 2); q es 0, 1, 2 ó 3; donde en cada caso, C₁₋₆alquilo puede estar opcionalmente sustituido con uno, dos, tres o más sustituyentes seleccionados del grupo que consiste en halógeno, hidroxilo, nitro, ciano, carboxi, C₂₋₆alquenilo, C₂₋₆alquinilo, C₁₋₆alcoxi, NRR, -NR-S(O)ʷ-C₁₋₆alquilo (donde w es 0, 1 ó 2), y S(O)ʷ-NRR (donde w es 0, 1 ó 2); C₁₋₆alcoxi puede estar opcionalmente sustituido con uno, dos, tres o más sustituyentes seleccionados del grupo que consiste en halógeno, hidroxilo, nitro, ciano, carboxi, C₁₋₆alquilo, NRR, -NR-S(O)ʷ-C₁₋₆alquilo (donde w es 0, 1 ó 2) y S(O)ʷ-NRR (donde w es 0, 1 ó 2); y sales aceptables farmacéuticamente y N-óxidos del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562218815P | 2015-09-15 | 2015-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106037A1 true AR106037A1 (es) | 2017-12-06 |
Family
ID=58289869
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102819A AR106040A1 (es) | 2015-09-15 | 2016-09-15 | Moduladores de la proteína core de la hepatitis b |
| ARP160102816A AR106037A1 (es) | 2015-09-15 | 2016-09-15 | Moduladores de la proteína core de la hepatitis b |
| ARP160102820A AR106041A1 (es) | 2015-09-15 | 2016-09-15 | Moduladores de la proteína core de la hepatitis b |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102819A AR106040A1 (es) | 2015-09-15 | 2016-09-15 | Moduladores de la proteína core de la hepatitis b |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102820A AR106041A1 (es) | 2015-09-15 | 2016-09-15 | Moduladores de la proteína core de la hepatitis b |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US10766890B2 (es) |
| EP (4) | EP3782626A1 (es) |
| JP (4) | JP2018531921A (es) |
| KR (3) | KR20180050406A (es) |
| CN (4) | CN112094264A (es) |
| AR (3) | AR106040A1 (es) |
| AU (4) | AU2016323297A1 (es) |
| CA (3) | CA2998793A1 (es) |
| CL (2) | CL2018000684A1 (es) |
| CY (1) | CY1123570T1 (es) |
| DK (1) | DK3349580T3 (es) |
| DO (1) | DOP2018000074A (es) |
| EA (3) | EA201890731A1 (es) |
| ES (2) | ES2905950T3 (es) |
| HK (2) | HK1259141A1 (es) |
| HR (1) | HRP20201812T1 (es) |
| HU (1) | HUE051872T2 (es) |
| IL (3) | IL258097A (es) |
| LT (1) | LT3349580T (es) |
| MX (4) | MX2018003207A (es) |
| MY (1) | MY198974A (es) |
| PH (3) | PH12018500571B1 (es) |
| PT (1) | PT3349580T (es) |
| RS (1) | RS61064B1 (es) |
| SG (1) | SG10202011103UA (es) |
| SI (1) | SI3349580T1 (es) |
| SM (1) | SMT202000630T1 (es) |
| TW (4) | TW201720802A (es) |
| WO (3) | WO2017048962A1 (es) |
| ZA (1) | ZA201802456B (es) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202001506UA (en) | 2014-03-13 | 2020-04-29 | Univ Indiana Res & Tech Corp | Hepatitis b core protein allosteric modulators |
| TW201720802A (zh) * | 2015-09-15 | 2017-06-16 | 艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
| US10987360B2 (en) | 2016-09-15 | 2021-04-27 | Assembly Biosciences, Inc. | Hepatitis B core protein modulators |
| FI3526323T3 (fi) | 2016-10-14 | 2023-06-06 | Prec Biosciences Inc | Hepatiitti B -viruksen genomissa oleville tunnistussekvensseille spesifisiä muokattuja meganukleaaseja |
| WO2018085619A1 (en) | 2016-11-07 | 2018-05-11 | Arbutus Biopharma, Inc. | Substituted pyridinone-containing tricyclic compounds, and methods using same |
| ES2874656T3 (es) | 2017-02-23 | 2021-11-05 | Fujian Cosunter Pharmaceutical Co Ltd | Compuesto tricíclico y aplicaciones del mismo |
| WO2018160878A1 (en) | 2017-03-02 | 2018-09-07 | Assembly Biosciences, Inc. | Cyclic sulfamide compounds and methods of using same |
| US11040965B2 (en) | 2017-03-13 | 2021-06-22 | Assembly Biosciences, Inc. | Process for making Hepatitis B core protein modulators |
| MA49014A (fr) | 2017-03-21 | 2020-02-05 | Arbutus Biopharma Corp | Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant |
| EA202091113A1 (ru) | 2017-11-02 | 2020-08-28 | Айкурис Гмбх Унд Ко. Кг | Новые высокоактивные аминотиазолзамещенные индол-2-карбоксамиды, активные в отношении вируса гепатита b (hbv) |
| KR20200083552A (ko) | 2017-11-02 | 2020-07-08 | 아이쿠리스 게엠베하 운트 코. 카게 | B형 간염 바이러스 (hbv)에 활성인 신규 고활성 피라졸로-피페리딘 치환된 인돌-2-카르복스아미드 |
| WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| IL278460B2 (en) * | 2018-05-03 | 2025-04-01 | Univ Emory | Regulators of orphan nuclear receptors for NASH and other metabolic diseases |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| TWI815887B (zh) * | 2018-05-15 | 2023-09-21 | 美商愛彼特生物製藥股份有限公司 | 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法 |
| TWI826492B (zh) | 2018-07-27 | 2023-12-21 | 加拿大商愛彼特生物製藥公司 | 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| JP2022500499A (ja) | 2018-09-07 | 2022-01-04 | ピク セラピューティクス， インコーポレイテッド | Ｅｉｆ４ｅ阻害剤およびその使用 |
| CR20210215A (es) | 2018-10-31 | 2021-06-17 | Gilead Sciences Inc | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| UY38435A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb) |
| UY38436A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
| JP2022506351A (ja) | 2018-11-02 | 2022-01-17 | アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Ｂ型肝炎ウイルス（ｈｂｖ）に対して活性を有する新規ウレア６，７－ジヒドロ－４ｈ－チアゾロ［５，４－ｃ］ピリジン |
| AR116946A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb) |
| AR117188A1 (es) | 2018-11-02 | 2021-07-21 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb) |
| UY38434A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) |
| TWI827760B (zh) | 2018-12-12 | 2024-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
| US20220213049A1 (en) * | 2019-01-17 | 2022-07-07 | Hoffmann-La Roche Inc. | Substituted chromen-4-one for the treatment and prophylaxis of hepatitis b virus infection |
| CA3129022C (en) | 2019-03-07 | 2023-08-01 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| KR102808642B1 (ko) | 2019-03-07 | 2025-05-14 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭 |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| KR20220002499A (ko) | 2019-04-30 | 2022-01-06 | 아이쿠리스 게엠베하 운트 코. 카게 | B형 간염 바이러스 (hbv)에 대해 활성인 신규 페닐 및 피리딜 우레아 |
| SG11202111493WA (en) | 2019-04-30 | 2021-11-29 | Aicuris Gmbh & Co Kg | Novel oxalyl piperazines active against the hepatitis b virus (hbv) |
| EP3962913A1 (en) | 2019-04-30 | 2022-03-09 | AiCuris GmbH & Co. KG | Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv) |
| US20220306647A1 (en) | 2019-04-30 | 2022-09-29 | Aicuris Gmbh & Co. Kg | Novel indole-2-carboxamides active against the hepatitus b virus (hbv) |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| EP3975996A1 (en) * | 2019-05-24 | 2022-04-06 | Assembly Biosciences, Inc. | Pharmaceutical compositions for the treatment of hbv |
| CR20210687A (es) | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| SI4037708T1 (sl) | 2019-09-30 | 2025-01-31 | Gilead Sciences, Inc. | Cepiva proti hbv in postopki zdravljenja hbv |
| CA3159096A1 (en) * | 2019-11-22 | 2021-05-27 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd | Crystal form of nucleoprotein inhibitor and use thereof |
| DK4069729T3 (da) | 2019-12-06 | 2025-04-07 | Prec Biosciences Inc | Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet |
| MX2022010944A (es) | 2020-03-03 | 2022-11-09 | Pic Therapeutics Inc | Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos. |
| US12162851B2 (en) | 2020-03-11 | 2024-12-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| KR20230022830A (ko) * | 2020-03-11 | 2023-02-16 | 녹시온 테라퓨틱스 인코포레이티드 | 하전된 이온 채널 차단제 및 사용 방법 |
| EP4121437A1 (en) | 2020-03-20 | 2023-01-25 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| AU2021261307A1 (en) * | 2020-04-22 | 2022-11-17 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of HBV |
| CN113929648A (zh) * | 2020-07-14 | 2022-01-14 | 浙江晖石药业有限公司 | 一种环丁烷-1,2-二甲酸酐及其中间体的制备方法 |
| JP7712352B2 (ja) | 2020-08-07 | 2025-07-23 | ギリアード サイエンシーズ， インコーポレイテッド | ホスホンアミドヌクレオチド類似体のプロドラッグ及びその薬学的使用 |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| US20240269142A1 (en) | 2021-05-13 | 2024-08-15 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| JP7686086B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物 |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023028235A1 (en) | 2021-08-25 | 2023-03-02 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| CN118019739A (zh) | 2021-08-25 | 2024-05-10 | 皮克医疗公司 | Eif4e抑制剂及其用途 |
| CN115521238B (zh) * | 2022-07-02 | 2024-05-31 | 甘肃瀚聚药业有限公司 | 一种n-甲基-2-(2-氯乙基)吡咯烷的制备方法 |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US688762A (en) * | 1901-06-19 | 1901-12-10 | Charles Weber | Toy. |
| GB1480553A (en) | 1976-06-03 | 1977-07-20 | Pfizer Ltd | Tricyclic sulphonamides |
| JPS58225074A (ja) | 1982-06-25 | 1983-12-27 | Chugai Pharmaceut Co Ltd | ジベンゾオキサゼピン誘導体 |
| GB9109557D0 (en) | 1991-05-02 | 1991-06-26 | Wellcome Found | Chemical compounds |
| US5512563A (en) | 1993-07-29 | 1996-04-30 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| DE19624659A1 (de) * | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| DE102004004928A1 (de) | 2004-01-31 | 2005-08-18 | Bayer Healthcare Ag | Dibenzoxazepine II |
| CA2625423A1 (en) * | 2005-10-17 | 2007-04-26 | Acadia Pharmaceuticals Inc. | Cb-1 modulating compounds and their use |
| WO2007056388A2 (en) * | 2005-11-07 | 2007-05-18 | The General Hospital Corporation | Compositions and methods for modulating poly (adp-ribose) polymerase activity |
| JP4042065B1 (ja) | 2006-03-10 | 2008-02-06 | 健治 吉田 | 情報処理装置への入力処理システム |
| WO2008036139A2 (en) | 2006-06-07 | 2008-03-27 | The Regents Of The University Of California | Inhibitors of mshc and homologs thereof, and methods of identifying same |
| WO2008118141A2 (en) | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
| AU2009274255A1 (en) * | 2008-07-23 | 2010-01-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of the plasmodial surface anion channel as antimalarials |
| EP2376495A4 (en) * | 2008-12-08 | 2012-10-31 | Vm Pharma Llc | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS |
| CN104530079B (zh) * | 2009-12-18 | 2017-10-20 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
| WO2012045194A1 (en) | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Benzodiazepinones as fak inhibitors for treatment of cancer |
| EP3085368A1 (en) * | 2011-07-01 | 2016-10-26 | Baruch S. Blumberg Institute | Sulfamoylbenzamide derivatives as antiviral agents against hbv infection |
| WO2013010069A1 (en) | 2011-07-13 | 2013-01-17 | Indiana University Research And Technology Corporation | Modified viral structural protein with antiviral activity |
| AR089671A1 (es) | 2012-01-06 | 2014-09-10 | Janssen R & D Ireland | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b |
| AU2013307328B2 (en) | 2012-08-28 | 2017-10-19 | Janssen Sciences Ireland Uc | Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| NZ743463A (en) | 2012-08-28 | 2019-09-27 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| BR112015004113A2 (pt) | 2012-09-10 | 2017-07-04 | Hoffmann La Roche | 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b |
| KR20150093685A (ko) | 2012-11-09 | 2015-08-18 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 | Hbv 어셈블리 이펙터의 대체 용도 |
| CA2892606A1 (en) | 2012-12-06 | 2014-06-12 | Baruch S. Blumberg Institute | Functionalized benzamide derivatives as antiviral agents against hbv infection |
| EA201591220A1 (ru) | 2012-12-27 | 2016-01-29 | Дрексел Юниверсити | Новые противовирусные агенты против инфекции вирусом гепатита в |
| RU2519546C1 (ru) | 2013-01-16 | 2014-06-10 | Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") | КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а |
| MX366123B (es) | 2013-02-28 | 2019-06-27 | Janssen Sciences Ireland Uc | Sulfamoil-arilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis b. |
| AR095426A1 (es) | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
| ES2892423T3 (es) | 2013-03-15 | 2022-02-04 | Celgene Car Llc | Compuestos de heteroarilo y usos de los mismos |
| EA027068B1 (ru) | 2013-04-03 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| US9266904B2 (en) | 2013-05-17 | 2016-02-23 | Hoffmann-La Roche Inc. | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection |
| CN105960400B (zh) | 2013-05-17 | 2019-05-31 | 爱尔兰詹森科学公司 | 氨磺酰基噻吩酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
| WO2014205138A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulator and uses thereof |
| WO2015017412A1 (en) * | 2013-07-29 | 2015-02-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | 11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine s-oxide derivatives and their use as dopamine d2 receptor antagonists |
| SG10202001506UA (en) | 2014-03-13 | 2020-04-29 | Univ Indiana Res & Tech Corp | Hepatitis b core protein allosteric modulators |
| MX2016016405A (es) | 2014-06-10 | 2017-04-06 | Basf Se | Compuestos de [1,2,4]triazol e imidazol sustituidos como fungicidas. |
| TW201720802A (zh) | 2015-09-15 | 2017-06-16 | 艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
-
2016
- 2016-09-14 TW TW105130076A patent/TW201720802A/zh unknown
- 2016-09-14 TW TW110118046A patent/TWI786639B/zh not_active IP Right Cessation
- 2016-09-14 TW TW105130078A patent/TWI730985B/zh not_active IP Right Cessation
- 2016-09-14 TW TW105130074A patent/TWI721016B/zh not_active IP Right Cessation
- 2016-09-15 JP JP2018513837A patent/JP2018531921A/ja active Pending
- 2016-09-15 HK HK19101106.8A patent/HK1259141A1/zh unknown
- 2016-09-15 PH PH1/2018/500571A patent/PH12018500571B1/en unknown
- 2016-09-15 AU AU2016323297A patent/AU2016323297A1/en not_active Abandoned
- 2016-09-15 CN CN202010540566.9A patent/CN112094264A/zh active Pending
- 2016-09-15 AR ARP160102819A patent/AR106040A1/es unknown
- 2016-09-15 US US15/760,387 patent/US10766890B2/en active Active
- 2016-09-15 JP JP2018513789A patent/JP2018531919A/ja active Pending
- 2016-09-15 SM SM20200630T patent/SMT202000630T1/it unknown
- 2016-09-15 MX MX2018003207A patent/MX2018003207A/es unknown
- 2016-09-15 HR HRP20201812TT patent/HRP20201812T1/hr unknown
- 2016-09-15 MY MYPI2018000361A patent/MY198974A/en unknown
- 2016-09-15 WO PCT/US2016/051949 patent/WO2017048962A1/en not_active Ceased
- 2016-09-15 WO PCT/US2016/051934 patent/WO2017048950A1/en not_active Ceased
- 2016-09-15 RS RS20201384A patent/RS61064B1/sr unknown
- 2016-09-15 HU HUE16847295A patent/HUE051872T2/hu unknown
- 2016-09-15 KR KR1020187010462A patent/KR20180050406A/ko not_active Withdrawn
- 2016-09-15 CN CN201680065137.2A patent/CN108348529A/zh active Pending
- 2016-09-15 MX MX2018003198A patent/MX392309B/es unknown
- 2016-09-15 CA CA2998793A patent/CA2998793A1/en not_active Abandoned
- 2016-09-15 KR KR1020187010461A patent/KR20180050405A/ko not_active Withdrawn
- 2016-09-15 KR KR1020187010455A patent/KR20180053363A/ko not_active Ceased
- 2016-09-15 EA EA201890731A patent/EA201890731A1/ru unknown
- 2016-09-15 EP EP20185808.1A patent/EP3782626A1/en not_active Withdrawn
- 2016-09-15 EP EP16847305.6A patent/EP3349581B8/en not_active Not-in-force
- 2016-09-15 PT PT168472959T patent/PT3349580T/pt unknown
- 2016-09-15 EP EP16847295.9A patent/EP3349580B1/en active Active
- 2016-09-15 WO PCT/US2016/051940 patent/WO2017048954A1/en not_active Ceased
- 2016-09-15 ES ES16847305T patent/ES2905950T3/es active Active
- 2016-09-15 HK HK19101078.2A patent/HK1258697A1/zh unknown
- 2016-09-15 CN CN201680065785.8A patent/CN108347943B/zh not_active Expired - Fee Related
- 2016-09-15 AU AU2016323305A patent/AU2016323305A1/en not_active Abandoned
- 2016-09-15 SI SI201630982T patent/SI3349580T1/sl unknown
- 2016-09-15 AR ARP160102816A patent/AR106037A1/es unknown
- 2016-09-15 JP JP2018513782A patent/JP7023838B2/ja not_active Expired - Fee Related
- 2016-09-15 CA CA2998741A patent/CA2998741C/en active Active
- 2016-09-15 EP EP16847298.3A patent/EP3349761B1/en not_active Not-in-force
- 2016-09-15 DK DK16847295.9T patent/DK3349580T3/da active
- 2016-09-15 AR ARP160102820A patent/AR106041A1/es unknown
- 2016-09-15 SG SG10202011103UA patent/SG10202011103UA/en unknown
- 2016-09-15 US US15/760,284 patent/US10377748B2/en active Active
- 2016-09-15 AU AU2016323293A patent/AU2016323293B2/en not_active Ceased
- 2016-09-15 US US15/760,343 patent/US10392379B2/en not_active Expired - Fee Related
- 2016-09-15 EA EA201890735A patent/EA201890735A1/ru unknown
- 2016-09-15 MX MX2018003206A patent/MX2018003206A/es unknown
- 2016-09-15 CN CN201680065139.1A patent/CN108347942B/zh not_active Expired - Fee Related
- 2016-09-15 ES ES16847295T patent/ES2831333T3/es active Active
- 2016-09-15 LT LTEP16847295.9T patent/LT3349580T/lt unknown
- 2016-09-15 CA CA2998803A patent/CA2998803A1/en not_active Abandoned
- 2016-09-15 EA EA201890736A patent/EA201890736A1/ru unknown
-
2018
- 2018-03-13 IL IL258097A patent/IL258097A/en unknown
- 2018-03-13 IL IL258099A patent/IL258099A/en unknown
- 2018-03-14 IL IL258124A patent/IL258124B/en active IP Right Grant
- 2018-03-14 MX MX2022005899A patent/MX2022005899A/es unknown
- 2018-03-15 DO DO2018000074A patent/DOP2018000074A/es unknown
- 2018-03-15 PH PH12018500573A patent/PH12018500573A1/en unknown
- 2018-03-15 PH PH12018500572A patent/PH12018500572A1/en unknown
- 2018-03-15 CL CL2018000684A patent/CL2018000684A1/es unknown
- 2018-04-13 ZA ZA2018/02456A patent/ZA201802456B/en unknown
-
2019
- 2019-05-28 CL CL2019001433A patent/CL2019001433A1/es unknown
- 2019-05-30 US US16/426,727 patent/US10968211B2/en not_active Expired - Fee Related
-
2020
- 2020-11-16 CY CY20201101088T patent/CY1123570T1/el unknown
-
2021
- 2021-01-04 US US17/140,800 patent/US11814376B2/en active Active
- 2021-01-18 JP JP2021005706A patent/JP7150903B2/ja active Active
- 2021-04-01 AU AU2021202065A patent/AU2021202065B2/en not_active Ceased
-
2023
- 2023-09-01 US US18/460,337 patent/US20240025890A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR106037A1 (es) | Moduladores de la proteína core de la hepatitis b | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| CL2018003492A1 (es) | Hepatitis b agentes antivirales. | |
| EA202090530A1 (ru) | Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич | |
| CL2018002528A1 (es) | Agentes anti virales de la hepatitis b. | |
| CL2018002803A1 (es) | Antagonistas de c5ar solubles | |
| MX2021005850A (es) | Heterociclos funcionalizados como agentes antivirales. | |
| EA201492214A1 (ru) | Ингибиторы вируса гепатита с | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| JOP20170045B1 (ar) | مركبات بيريدون رباعية الحلقة كمضادات فيروسية | |
| ECSP18073264A (es) | Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue | |
| ECSP12012103A (es) | Inhibidores de virus flaviviridae. | |
| EA201492205A1 (ru) | Макроциклические ингибиторы вирусов flaviviridae | |
| AR103251A1 (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
| ECSP12012104A (es) | Inhibidores de virus flaviviridae | |
| EA201492209A1 (ru) | Макроциклические ингибиторы вирусов flaviviridae | |
| EA201492188A1 (ru) | Макроциклические ингибиторы вирусов flaviviridae | |
| CY1119842T1 (el) | Συντηγμενες τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις ιντεγκρασης hiv | |
| MX2018008095A (es) | Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih. | |
| EA200901241A1 (ru) | Соединения для лечения гепатита с | |
| AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| CO2018009559A2 (es) | Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue | |
| JOP20190130A1 (ar) | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) | |
| PE20140302A1 (es) | Inhibidores del virus de la hepatitis c | |
| EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |